AEC/BC02

Vaccine Platform

Protein / Adjuvant

Phase of Development

Phase 2a

Candidate Overview

AEC/BC02 is a recombinant Mycobacterium tuberculosis freeze-dried vaccine made of Ag85B and ESAT6-CFP10 as Mtb antigens, combined with a proprietary adjuvant system, BC02.

Sponsor / Lead Developer: Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.

Primary Indication: Prevention of TB disease

Target Population(s): Adults, Elderly, and People with Mtb infection

Clinical Trials

ACTIVE TRIALS
Registry NumberNCT05284812
Clinical Trial PhasePhase 2a
StatusActive
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults
Elderly
People with Mtb infection
COMPLETED TRIALS
Registry NumberNCT04239313
Clinical Trial PhasePhase 1
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults
Registry NumberNCT03026972
Clinical Trial PhasePhase 1
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults

Related Publications

  1. Therapeutic evaluation of antibiotics combined with recombinant tuberculosis vaccine AEC/BC02 in a guinea pig model of Mycobacterium tuberculosis infection (Chin J Microbiol Immunol, 2018, Chinese)
  2. Therapeutic evaluation of isoniazid in combination with recombinant tuberculosis vaccine AEC/BC02 in guinea pigs infected with Mycobacterium tuberculosis (Chin J Antibuberc, 2017, Chinese)
  3. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants (FEMS Immunol Med Microbiol, 2010)